Explore the categories so you can find more about your search.
Categorie > Crohn's
Hope For Crohn's Patients With Fistulas Found In HUMIRA/Adalimumab
Categorie : Crohn'sAt the recent European Crohn's and Colitis Organization (ECCO) annualmeeting in Lyon, France, Abbott Laboratories announced that HUMIRA(Adalimumab) is successful in the treatment of fistulas in susceptibleCrohn's patients. Crohn'sDisease (CD) is a gastrointestinal disorder which is indicated bychron ...
read more 
Wed Mar 2008
Early Data On Cimzia® Shows Promise In Crohn's Patients Without Infliximab
Categorie : Crohn'sDatafrom the WELCOME trial presented at the third congress of the EuropeanCrohn's and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia® (certolizumab pegol) is effective in Crohn's patientsshowing intolerance or no response to infliximab. Crohn'sDisease (CD) is a gastrointestinal d ...
read more Wed Mar 2008
New Treatment Strategy For Crohn's Disease Shows Promise
Categorie : Crohn'sWhen treating patients with Crohn's disease, early use of an intensivecombined immunosuppression (CI) in combination withconventional management is more effective than the current standard,treatment with corticosteroids. These outcomes were reported in anArticle in the February 23, 2008 issue of The ...
read more Wed Mar 2008
Inflammatory Bowel Disease May Mimic Gynecological Disorders In Its Clinical Presentation
Categorie : Crohn'sEndometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract. It usually occurs between 30 and 40 years of age. Four to 17% of menstruating women develop endometriosis. When the disease invo ...
read more Wed Mar 2008
Improved Treatment For Crohn's Disease
Categorie : Crohn'sAn international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease."Our study clearly demonstrated that this alternative treatment met ...
read more Wed Mar 2008
Bacteria In Cows' Milk May Cause Crohn's Disease
Categorie : Crohn'sCrohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli b ...
read more Tue Feb 2008
Differing Physician And Patient Perceptions Regarding Impact Of UC Revealed by Nationwide Survey
Categorie : Crohn'sNearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented at the 2007 Crohn's & Co ...
read more Tue Feb 2008
Callisto Announces Presentation On Guanilib At 2007 Crohn's And Colitis Foundation National Research And Clinical Conference
Categorie : Crohn'sCallisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical data on Guanilib at the Crohn's and ...
read more Tue Feb 2008
Asacol 800mg MR Tablets Dosed At 4.8g/Day Herald Fast Symptom Relief And Improved Quality Of Life For Moderately Active UC Patients
Categorie : Crohn'sProcter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of mild to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn's ileo-colitis pat ...
read more Tue Feb 2008
FDA Approves Tysabri® For The Treatment Of Moderate-To-Severe Crohn's Disease
Categorie : Crohn'sElan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for TYSABRI® (natalizumab). ...
read more Tue Feb 2008
FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease
Categorie : Crohn'sThe U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies. Crohn's disease patien ...
read more Tue Feb 2008
Intestinal Inflammation Decreased By Il-22 Gene
Categorie : Crohn'sThere are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General ...
read more Tue Feb 2008
Scientists Find How Bacteria In Cows' Milk May Cause Crohn's Disease
Categorie : Crohn'sScientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team ...
read more Tue Feb 2008
Pivotal CIMZIA? Data In Crohn's Disease Published In New England Journal Of Medicine
Categorie : Crohn'sTwo pivotal Phase III clinical trials demonstrating the safety and sustained efficacy of CIMZIA? (certolizumab pegol) in moderate-to-severe Crohn's disease (CD) were published in two articles in the July 19 issue of the New England Journal of Medicine (NEJM). [click link for full article] ...
read more Wed Dec 2007
First-time Link Between Food Intolerance And Illness
Categorie : Crohn'sResearchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.A six-month programme has shown potential links with foodstuffs and Crohn's Disease, and ulcerative colitis.The discovery could prompt an entire rethink in the m ...
read more Wed Dec 2007
Kids With Crohn's Disease Find Comfort, Leading-edge Treatment At Pediatric Infusion Center
Categorie : Crohn'sSeventeen-year-old Eliot Drieband explains what it's like to have Crohn's disease a type of inflammatory bowel disease in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for teens and being a ...
read more Wed Dec 2007
Remicade® Receives EU Approval As First And Only Biologic Treatment For Paediatric Crohn's Disease
Categorie : Crohn'sThe European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary ...
read more Wed Dec 2007
Asacol® 800mg Mr Tablets Approved For Ulcerative Colitis (UC), Maintenance Of Remission Of UC And Crohn's Ileo-Colitis
Categorie : Crohn'sProcter & Gamble Pharmaceuticals (NYSE: P&G)announced today that Asacol® (mesalazine) 800mg Modified Release (MR) tablets have beenapproved for the treatment of mild to moderate ulcerative colitis (UC) and maintenance ofremission of UC and Crohn's ileo-colitis in the United Kingdom by the Medicines ...
read more Wed Dec 2007
Joint FDA Advisory Committee Recommends Approval Of TYSABRI® For The Treatment Of Moderate To Severe Crohn's Disease
Categorie : Crohn'sElan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 12 in favor to 3 opposed, with 2 abstaining, to recommen ...
read more Wed Dec 2007
UCB To Appeal European Negative Opinion On CIMZIA(R) For The Treatment Of Patients With Crohn's Disease
Categorie : Crohn'sUCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with ...
read more Wed Dec 2007
Custom Search
